Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), causes an estimated 900,000 events and 100,000 deaths annually in the United States, with incidence rising sharply in older adults. From the AAVBC's perspective, value-based VTE care begins by preventing PE through early recognition of DVT, followed by deliberate reassessment rather than automatic discontinuation of anticoagulation after 3 months. Primary care should document whether a VTE was provoked or unprovoked, reassess recurrence and bleeding risk at 3–6 months, and individualize extended therapy rather than relying on prescribing inertia. Equally important, anticoagulant selection should balance efficacy, safety, renal function, adherence, and affordability. For appropriate patients with preserved renal function, generic dabigatran represents an underused, evidence-based, substantially lower-cost alternative to routine prescribing of brand-name apixaban.
Drawing from current AHA/ACC, ASH, ACP, and CHEST guidance, AAVBC's DVT and Pulmonary Embolism Quick Reference Guide focuses on the clinical decisions where primary care creates the greatest value, including age-adjusted D-dimer strategies to safely reduce unnecessary imaging, Wells and PESI risk stratification, ICD-10 coding, HCC/RAF mapping, MEAT documentation, and individualized anticoagulant selection. It also highlights documentation practices supporting MIPS #514 (Diagnostic Delay of Venous Thromboembolism), emphasizing timely recognition, explicit duration decisions, and longitudinal accountability to improve outcomes, quality performance, and cost stewardship.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of DVT and pulmonary embolism — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
Venous thromboembolism (VTE), encompassing deep vein thrombosis (DVT) and pulmonary embolism (PE), causes an estimated 900,000 events and 100,000 deaths annually in the United States, with incidence rising sharply in older adults. From the AAVBC's perspective, value-based VTE care begins by preventing PE through early recognition of DVT, followed by deliberate reassessment rather than automatic discontinuation of anticoagulation after 3 months. Primary care should document whether a VTE was provoked or unprovoked, reassess recurrence and bleeding risk at 3–6 months, and individualize extended therapy rather than relying on prescribing inertia. Equally important, anticoagulant selection should balance efficacy, safety, renal function, adherence, and affordability. For appropriate patients with preserved renal function, generic dabigatran represents an underused, evidence-based, substantially lower-cost alternative to routine prescribing of brand-name apixaban.
Drawing from current AHA/ACC, ASH, ACP, and CHEST guidance, AAVBC's DVT and Pulmonary Embolism Quick Reference Guide focuses on the clinical decisions where primary care creates the greatest value, including age-adjusted D-dimer strategies to safely reduce unnecessary imaging, Wells and PESI risk stratification, ICD-10 coding, HCC/RAF mapping, MEAT documentation, and individualized anticoagulant selection. It also highlights documentation practices supporting MIPS #514 (Diagnostic Delay of Venous Thromboembolism), emphasizing timely recognition, explicit duration decisions, and longitudinal accountability to improve outcomes, quality performance, and cost stewardship.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of DVT and pulmonary embolism — moving far beyond quick-reference essentials. These guides provide an integrated review of epidemiology, diagnostic strategy, staging, coding logic, MEAT-aligned documentation examples, treatment guidelines, review vulnerabilities, and cost-utilization considerations. The Deep-Dive combines evidence-informed clinical guidance with practical operational tools to support a deeper understanding of disease complexity and provide multidisciplinary teams with strategies to thrive within value-based frameworks.
